Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1056634-68-4
Formula :	C₂₃H₂₂N₆O₂
M.W :	414.46
SMILES Code :	O=C(NCC#N)C1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1
Synonyms :	CYT387; LM-1149; CYT11387
MDL No. :	MFCD16038899
InChI Key :	ZVHNDZWQTBEVRY-UHFFFAOYSA-N
Pubchem ID :	25062766

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

CBL-mutant iPSC-derived myeloid cells	1 uM	60 minutes	Inhibited JAK/STAT signaling, significantly decreased pJAK2 and pSTAT5 levels	PMC6286697
HHSteCs	2 µM	24 hours	Momelotinib attenuated the phosphorylation of STAT1 and reduced COL1A1 production.	PMC8251927
Colon cancer cells	1 nM to 1 μM	96 hours	To evaluate the inhibitory effect of Momelotinib on the proliferation of colon cancer cells, the results showed that Momelotinib significantly inhibited cell proliferation	PMC6343337
8988T cells	5 μM	60 minutes	inhibits autophagy and reduces PD-L1 expression	PMC4891226
8988T-LC3-GFP cells	5 μM	60 minutes	inhibits autophagy	PMC4891226
U937-derived macrophages	25 ng/mL	72 hours	IL-11 enhances pro-tumoral features of macrophages via the AXL-STAT3 signaling pathway, upregulating CD44 expression.	PMC10577802
AML cell lines	2.5 µM	6 hours	To evaluate the effect of Momelotinib on AML cell lines, results showed that Momelotinib inhibited MYC mRNA and protein expression.	PMC6290107
MOLM14 cells	0.625 µM	2 hours	To evaluate the effect of Momelotinib on MOLM14 cells, results showed that Momelotinib significantly reduced YB-1 phosphorylation.	PMC6290107
BaF3 cells	325 nM	72 hours	Momelotinib effectively suppressed the proliferation of BaF3-JAK2V617F cells with an IC50 of 325 nM.	PMC8864657
MV4-11 cells	165 nM	2 hours	Momelotinib significantly inhibited pFLT3 and pSTAT5 levels in MV4-11 cells within 2 hours, with an IC50 of 165 nM.	PMC8864657

mice	cerulein-induced pancreatitis model	oral	100 mg/kg	Once every 5 days for 4 weeks	inhibits autophagy and reduces inflammation	PMC4891226
Nu/J mice	A549 lung cancer xenograft model	Oral	50 mg/kg	daily for 2 days	Momelotinib inhibits JAK1/2 signaling, reducing recruitment of tumor-associated macrophages and suppressing tumor growth.	PMC10577802
NSG mice	human AML xenograft model	oral	10 mg/kg	once daily for 30 days	To evaluate the therapeutic effect of Momelotinib in the AML xenograft model, results showed that Momelotinib significantly reduced tumor burden and decreased IKBKE, YB-1 phosphorylation, and MYC expression.	PMC6290107
Mice	NSGS mice	Intraperitoneal injection	10 mg/kg	daily for 10 days	Momelotinib effectively suppressed leukemic progression in the NSGS mouse model, whereas gilteritinib treatment was ineffective.	PMC8864657

{[proInfo.proName]}

CAS No.: 1056634-68-4

{[proInfo.proName]}

CAS No.: 1056634-68-4

Alternative Products

Product Details of Momelotinib

Safety of Momelotinib

Related Pathways of Momelotinib

Isoform Comparison

Biological Activity

Protocol

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02251821	Primary Myelofibrosis ... More >> Secondary Myelofibrosis Less <<	Phase 2	Recruiting	-	United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Rachel B. Salit 206-667-1317 rsalit@fredhutch.org Principal Investigator: Rachel B. Salit Less <<
NCT02206763	EGFR Mutated EGFR TKI Naive Me... More >>tastatic NSCLC Less <<	Phase 1	Terminated	-	United States, California ... More >> Duarte, California, United States Palo Alto, California, United States Whittier, California, United States Less <<
NCT01998828	Polycythemia Vera\|Essential Th... More >>rombocythemia Less <<	PHASE2	TERMINATED	2015-05-07	Scottsdale, Arizona, United St... More >>ates\|Whittier, California, United States\|Tupelo, Mississippi, United States\|Saint Louis, Missouri, United States\|Houston, Texas, United States\|Frankston, Victoria, Australia\|Parkville, Victoria, Australia\|Vancouver, British Columbia, Canada\|Toronto, Ontario, Canada\|Montreal, Quebec, Canada\|La Tronche, France\|Nantes Cedex 1, France\|Paris, France\|Dresden, Germany\|Minden, Germany Less <<
NCT01969838	Primary Myelofibrosis ... More >> Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Less <<	Phase 3	Active, not recruiting	March 2019	-
NCT02101021	Metastatic Pancreatic Ductal A... More >>denocarcinoma Less <<	Phase 3	Terminated	-	United States, California ... More >> Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Indiana Indiana University Health Goshen Center for Cancer Care Goshen, Indiana, United States, 46506 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Washington Northwest Medical Specialties, PLLC Tacoma, Washington, United States, 98405 Less <<
NCT02101268	Primary Myelofibrosis (PMF) ... More >> Post-polycythemia Vera (Post-PV) Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Less <<	Phase 3	Active, not recruiting	March 2019	-
NCT02101021	-		Terminated	-	-
NCT02515630	Primary Myelofibrosis (PMF) ... More >> Post-polycythemia Vera (Post-PV) Myelofibrosis Postessential Thrombocythemia (Post-ET) Myelofibrosis Less <<	Phase 2	Completed	-	United States, Arizona ... More >> Phoenix, Arizona, United States United States, California Los Angeles, California, United States Orange, California, United States United States, Florida Jacksonville, Florida, United States United States, Maryland Baltimore, Maryland, United States United States, Michigan Ann Arbor, Michigan, United States United States, Missouri Saint Louis, Missouri, United States United States, New York Bronx, New York, United States New York, New York, United States United States, North Carolina Durham, North Carolina, United States United States, Ohio Cleveland, Ohio, United States United States, Texas Houston, Texas, United States Canada, Ontario Toronto, Ontario, Canada Less <<
NCT02258607	Relapsed Metastatic KRAS-Mutat... More >>ed Non-Small Cell Lung Cancer Less <<	Phase 1	Terminated	-	United States, California ... More >> Duarte, California, United States Sacramento, California, United States United States, Massachusetts Boston, Massachusetts, United States United States, Virginia Fairfax, Virginia, United States United States, Washington Spokane, Washington, United States Less <<
NCT01423058	Primary Myelofibrosis\|Post-Pol... More >>ycythemia Vera\|Post-Essential Thrombocythemia Myelofibrosis Less <<	PHASE1\|PHASE2	COMPLETED	2025-06-14	Mayo Clinic, Scottsdale, Arizo... More >>na, 85259, United States\|Mayo Clinic, Jacksonville, Florida, 32224, United States\|MD Anderson Cancer Center, The University of Texas, Houston, Texas, 77030, United States\|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, 84108, United States\|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada\|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada Less <<
NCT01236638	Primary Myelofibrosis\|Post-Pol... More >>ycythemia Vera Myelofibrosis\|Post-Essential Thrombocythemia Myelofibrosis Less <<	PHASE2	COMPLETED	2025-06-14	Stanford Cancer Center, Stanfo... More >>rd, California, 94305-5821, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States\|Mayo Clinic, Rochester, Minnesota, 55905, United States\|The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia\|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada\|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada Less <<
NCT02124746	Primary Myelofibrosis\|Post-Pol... More >>ycythemia Vera Myelofibrosis\|Post-Essential Thrombocythemia Myelofibrosis\|Polycythemia Vera\|Essential Thrombocythemia Less <<	PHASE2	COMPLETED	2018-12-06	Scottsdale, Arizona, United St... More >>ates\|Orange, California, United States\|Stanford, California, United States\|Whittier, California, United States\|Jacksonville, Florida, United States\|Baltimore, Maryland, United States\|Boston, Massachusetts, United States\|Ann Arbor, Michigan, United States\|Rochester, Minnesota, United States\|Saint Louis, Missouri, United States\|Bronx, New York, United States\|New York, New York, United States\|Cleveland, Ohio, United States\|Houston, Texas, United States\|Salt Lake City, Utah, United States\|Frankston, Victoria, Australia\|Parkville, Victoria, Australia\|Toronto, Ontario, Canada\|Montreal, Quebec, Canada\|La Tronche, France\|Paris, France\|Minden, Germany Less <<
NCT02244489	Relapsed/Refractory Metastatic... More >> Pancreatic Ductal Adenocarcinoma Less <<	Phase 1	Terminated	-	United States, Arizona ... More >> Scottsdale Healthcare Research Institute Scottsdale, Arizona, United States, 85258 United States, California Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Tennessee Tennessee Oncology Nashville, Tennessee, United States, 37203 United States, Virginia Virginia Cancer Specialists, PC Fairfax, Virginia, United States, 22031 Less <<
NCT03441113	Post-polycythemia Vera Myelofi... More >>brosis (Post-PV MF) Primary Myelofibrosis (PMF) Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Less <<	Phase 2	Enrolling by invitation	June 2020	-
NCT00935987	Primary Myelofibrosis\|Post-Pol... More >>ycythemia Vera Myelofibrosis\|Post-Essential Thrombocythemia Myelofibrosis Less <<	PHASE1\|PHASE2	COMPLETED	2025-04-12	Stanford Cancer Center, Stanfo... More >>rd, California, 94305-5821, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States\|Mayo Clinic, Rochester, Minnesota, 55905, United States\|The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia\|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada\|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada Less <<
NCT05582083	Myelofibrosis\|Primary Myelofib... More >>rosis Less <<		NO_LONGER_AVAILABLE	-	-

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed